Memorial-Sloan Kettering Cancer Institute study finding that trimetrexate enhances the efficacy of 5-FU will be presented at the American Society of Clinical Oncology conference in Orlando the week of May 17, U.S. Bioscience's Philip Schein advises. The company has been studying trimetrexate glucuronate, tradenamed Neutrexin, for several indications, including treatment of advanced non-small cell lung cancer, prostate cancer and pancreatic cancers. An NDA is pending for second-line treatment of Pneumocystis carinii pneumonia.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth